INNOCOLL: Rosen Law Firm Reminds Innocoll Holdings plc Investors of Important Deadline in First-Filed Case by Firm - INNL
27 févr. 2017 18h02 HE
|
The Rosen Law Firm PA
NEW YORK, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Innocoll Holdings plc securities (NASDAQ:INNL) from November 3, 2016 through...
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Innocoll Holdings plc - INNL
08 févr. 2017 18h07 HE
|
The Rosen Law Firm PA
NEW YORK, Feb. 08, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Innocoll Holdings plc...
Innocoll Holdings plc to Present at the Piper Jaffray Annual Healthcare Conference
23 nov. 2016 08h00 HE
|
Innocoll Holdings plc
ATHLONE, Ireland, Nov. 23, 2016 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical and medical device company with late stage development programs targeting...
Innocoll Holdings plc Announces Third Quarter 2016 Financial and Operating Results and Provides Corporate Update
22 nov. 2016 08h00 HE
|
Innocoll Holdings plc
ATHLONE, Ireland, Nov. 22, 2016 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical company with late stage development programs targeting areas of...
Innocoll to Report Third Quarter 2016 Financial Results and Host Webcast and Conference Call on November 22, 2016
15 nov. 2016 08h30 HE
|
Innocoll Holdings plc
ATHLONE, Ireland, Nov. 15, 2016 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical company with late stage development programs targeting areas of...
Innocoll Holdings plc to Present at the Stifel 2016 Healthcare Conference
14 nov. 2016 08h30 HE
|
Innocoll Holdings plc
ATHLONE, Ireland, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical and medical device company with late stage development programs targeting...
Innocoll Announces Top-Line Data From Phase 3 Trials With COGENZIA and NDA Submission for XARACOLL
03 nov. 2016 16h31 HE
|
Innocoll Holdings plc
COACT-1 and COACT-2 Phase 3 clinical trials for COGENZIA did not achieve statistical significance in improving clinical cure in diabetic foot infections (DFI)New Drug Application (NDA) for XARACOLL...
Innocoll Holdings plc to Present at the Morgan Stanley Global Healthcare Conference
07 sept. 2016 16h01 HE
|
Innocoll Holdings plc
ATHLONE, Ireland, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical and medical device company with late stage development programs targeting...
Innocoll Holdings plc Announces Second Quarter 2016 Financial and Operating Results and Provides Corporate Update
17 août 2016 08h00 HE
|
Innocoll Holdings plc
ATHLONE, Ireland, Aug. 17, 2016 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical company with late stage development programs targeting areas of...
Innocoll to Report Second Quarter 2016 Financial Results and Host Webcast and Conference Call on August 17, 2016
11 août 2016 16h01 HE
|
Innocoll Holdings plc
ATHLONE, Ireland, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (Nasdaq:INNL), a global, specialty pharmaceutical company with late stage development programs targeting areas of...